A comprehensive summary of the FDA Form 483 issued to Aurobindo Pharma Limited,
Unit VII (Inspection dated Jan 28 – Feb 10 2026), including what went wrong at the quality system level — root causes, system failures, and broader quality-management insights
Why “Precision” Isn’t Enough for the FDA: A Lesson in Method Equivalency.
I’ve been diving deep into a specific FDA 483 observation recently that every Analytical Lead and QA Manager should keep on their radar. It highlights a common trap: confusing
Regulatory Enforcement Alert — FDA Cracks Down on Misleading Claims in GLP-1 & Compounded Drug Marketing.
The pharmaceutical and compounding landscape is witnessing a significant regulatory shift.The U.S. Food and Drug Administration (FDA) is actively enforcing federal drug marketing a
Another FDA 483 highlighting critical data integrity failures at a sterile manufacturing site in India.
A recent U.S. Food and Drug Administration 483 inspection at Maiva Pharma Pvt. Ltd. (Hosur, Tamil Nadu, India) identified serious deficiencies in the control of original CGMP manuf
FDA Issues Warning Letter to Novo Nordisk Inc. Regarding Postmarketing Safety Reporting
The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to Novo Nordisk Inc. (NNI) following an inspection conducted between January and February 2025. The inspecti